慢性肾脏病相关血管疾病中的固有免疫
该综述阐述固有免疫系统在慢性肾脏病(CKD)相关心血管疾病中的作用,重点讨论Toll样受体(TLR)和炎症小体复合物通过识别内源性配体参与高血压、动脉粥样硬化病变形成和血管钙化的机制,并指出多种调控固有免疫激活的药物正在心血管研究中,尚需大型临床研究及纳入CKD患者的试验评估其疗效。
要点
- TLR和炎症小体复合物参与CKD相关心血管疾病的发病机制。
- TLR和炎症小体激活与动脉高血压、动脉粥样硬化病变形成及血管钙化相关。
- 固有免疫系统如何参与CKD相关心血管疾病的详细分子机制尚不清楚。
核心结论
- 固有免疫系统通过TLR和炎症小体参与CKD相关心血管疾病的 pathogenesis,但详细分子机制尚不清楚。
- 多种调控固有免疫激活的药物是当前心血管研究的焦点,需大型临床研究及纳入CKD患者的试验评估其疗效。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- TLR和炎症小体复合物在白细胞及内皮细胞、成纤维细胞等多种细胞类型中表达。
- TLR激活导致核因子κB依赖性促炎介质表达,炎症小体将白细胞介素-1β等细胞因子切割为生物活性形式。
- 多种内源性配体参与形成CKD特异性促炎微环境。
- TLR和炎症小体激活与动脉高血压、动脉粥样硬化血管病变形成及血管钙化相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 固有免疫系统如何参与CKD相关心血管疾病的详细分子机制尚不清楚。
- 需大型临床研究提供调控固有免疫药物在普通人群中降低心血管发病率和死亡率的治疗适用性信息。
- 需纳入CKD患者的进一步试验评估这些药物对CKD相关心血管疾病的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is associated with an increased risk for cardiovascular events. Therefore, the activation of the innate immune system plays an important role. In contrast to the adaptive immunity, unspecific recognition of conserved endogenous and exogenous structures by pattern recognition receptors (PRRs) represents a key feature of the innate immunity. Of these PRRs, Toll-like receptors (TLRs) as well as the inflammasome complex have been documented to be involved in the pathogenesis of cardiovascular diseases (CVDs). They are not only expressed in leukocytes but also in a variety of cell types such as endothelial cells or fibroblasts. While activation of TLRs on the cell surface leads to nuclear factor κB-dependent expression of pro-inflammatory mediators, the inflammasome is a cytosolic multimeric protein complex, which cleaves cytokines such as interleukin-1β into their biologically active forms. Several endogenous ligands for these PRRs have been identified as contributing to the development of a CKD-specific pro-inflammatory microenvironment. Notably, activation of TLRs as well as the inflammasome is associated with arterial hypertension, formation of atherosclerotic vascular lesions and vascular calcification. However, detailed molecular mechanisms on how the innate immune system contributes to CKD-associated CVDs are as yet poorly understood. Currently, several agents modulating the activation of the innate immune system are the focus of cardiovascular research. Large clinical studies will provide further information on the therapeutic applicability of these substances to reduce cardiovascular morbidity and mortality in the general population. Further trials including patients with CKD will be necessary to assess their effects on CKD-associated CVD.
引用
- Zewinger S, Schumann T, Fliser D, et al. Innate immunity in CKD-associated vascular diseases. Nephrol Dial Transplant. 2015. PMID: 26454223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。